Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Chrysalyne D. Schmults(Dana-Farber Brigham Cancer Center), Rachel Blitzblau(Cancer Institute (WIA)), Sumaira Z. Aasi(Cancer Institute (WIA)), Murad Alam(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Arya Amini(City Of Hope National Medical Center), Kristin Bibee(Sidney Kimmel Comprehensive Cancer Center), Jeremy S. Bordeaux(Cleveland Clinic), Pei-Ling Chen(Moffitt Cancer Center), Carlo M. Contreras(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Dominick J. DiMaio(Susan Thompson Buffett Foundation), Jessica M. Donigan(University of Utah), Jeffrey M. Farma(Fox Chase Cancer Center), Karthik Ghosh(WinnMed), Kelly L. Harms, Alan L. Ho(Memorial Sloan Kettering Cancer Center), John N. Lukens(University of Pennsylvania), Lawrence A. Mark(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), Theresa Medina(University of Colorado Cancer Center), Kishwer S. Nehal(Memorial Sloan Kettering Cancer Center), Paul Nghiem(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Kelly Olino(Yale Cancer Center), Soohyung Park(UC San Diego Health System), Tejesh Patel(University of Tennessee Health Science Center), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Jason T. Rich(Barnes-Jewish Hospital), Aleksandar Sekulić(WinnMed), Ashok R. Shaha(Memorial Sloan Kettering Cancer Center), Divya Srivastava(Southwestern Medical Center), Valencia D. Thomas(The University of Texas MD Anderson Cancer Center), Courtney M. Tomblinson(Breast Cancer Research Foundation), Puja Venkat(University of Colorado Cancer Center), Yaohui Xu(University of Wisconsin Carbone Cancer Center), Siegrid S. Yu(UCSF Helen Diller Family Comprehensive Cancer Center), Mehran Yusuf(University of Colorado Cancer Center), Beth McCullough(National Comprehensive Cancer Network), Sara Espinosa(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
November 1, 2023
10.6004/jnccn.2023.0056
Cited by 114Open Access
Full Text

Abstract

Basal cell carcinoma (BCC) is the most common form of skin cancer in the United States. Due to the high frequency, BCC occurrences are not typically recorded, and annual rates of incidence can only be estimated. Current estimated rates are 2 million Americans affected annually, and this continues to rise. Exposure to radiation, from either sunlight or previous medical therapy, is a key player in BCC development. BCC is not as aggressive as other skin cancers because it is less likely to metastasize. However, surgery and radiation are prevalent treatment options, therefore disfigurement and limitation of function are significant considerations. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline an updated risk stratification and treatment options available for BCC.

Related Papers

No related papers found

Powered by citation graph analysis